INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 157 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q3 2023. The put-call ratio across all filers is 2.78 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $606,258 | +40.0% | 32,700 | +213.2% | 0.00% | 0.0% |
| Q3 2020 | $433,000 | +83.5% | 10,441 | +112.0% | 0.00% | – |
| Q2 2020 | $236,000 | -51.4% | 4,925 | -36.2% | 0.00% | -100.0% |
| Q1 2020 | $486,000 | -74.1% | 7,724 | -49.1% | 0.00% | -50.0% |
| Q4 2019 | $1,879,000 | +94.5% | 15,165 | +3.6% | 0.00% | +100.0% |
| Q3 2019 | $966,000 | -17.0% | 14,640 | +0.1% | 0.00% | 0.0% |
| Q2 2019 | $1,164,000 | -8.6% | 14,631 | +28.4% | 0.00% | 0.0% |
| Q1 2019 | $1,274,000 | +53.7% | 11,391 | +35.3% | 0.00% | 0.0% |
| Q4 2018 | $829,000 | -28.5% | 8,418 | -8.2% | 0.00% | 0.0% |
| Q3 2018 | $1,159,000 | +76.9% | 9,169 | +17.6% | 0.00% | 0.0% |
| Q2 2018 | $655,000 | +36.5% | 7,800 | 0.0% | 0.00% | – |
| Q1 2018 | $480,000 | +5.3% | 7,800 | 0.0% | 0.00% | – |
| Q4 2017 | $456,000 | +57.2% | 7,800 | +56.0% | 0.00% | – |
| Q3 2017 | $290,000 | -69.6% | 5,000 | -35.7% | 0.00% | -100.0% |
| Q2 2017 | $953,000 | +7.2% | 7,772 | -1.3% | 0.00% | 0.0% |
| Q1 2017 | $889,000 | +7.8% | 7,872 | +3.6% | 0.00% | 0.0% |
| Q4 2016 | $825,000 | -47.5% | 7,595 | -22.2% | 0.00% | -50.0% |
| Q3 2016 | $1,571,000 | +30.0% | 9,759 | +15.3% | 0.00% | +100.0% |
| Q2 2016 | $1,208,000 | -22.9% | 8,465 | -30.6% | 0.00% | -50.0% |
| Q1 2016 | $1,566,000 | -13.2% | 12,195 | +1.2% | 0.00% | 0.0% |
| Q4 2015 | $1,805,000 | -60.9% | 12,045 | -56.8% | 0.00% | -66.7% |
| Q3 2015 | $4,621,000 | -28.6% | 27,860 | +4.0% | 0.01% | -14.3% |
| Q2 2015 | $6,469,000 | -46.5% | 26,800 | -37.5% | 0.01% | -50.0% |
| Q1 2015 | $12,085,000 | +80.6% | 42,855 | -0.1% | 0.01% | +100.0% |
| Q4 2014 | $6,690,000 | -2.1% | 42,885 | +48.6% | 0.01% | -12.5% |
| Q3 2014 | $6,831,000 | +132.0% | 28,860 | +131.9% | 0.01% | +100.0% |
| Q2 2014 | $2,945,000 | -43.1% | 12,445 | -20.7% | 0.00% | -33.3% |
| Q1 2014 | $5,178,000 | – | 15,700 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Samsara BioCapital, LLC | 640,688 | $9,514,000 | 1.49% |
| CM Management, LLC | 45,000 | $668,000 | 0.50% |
| EULAV Asset Management | 660,000 | $9,801,000 | 0.26% |
| DLD Asset Management, LP | 225,200 | $3,346,000 | 0.24% |
| Virtus ETF Advisers LLC | 21,387 | $318,000 | 0.14% |
| GSA CAPITAL PARTNERS LLP | 79,145 | $1,175,000 | 0.12% |
| Hennion & Walsh Asset Management, Inc. | 136,720 | $2,030,000 | 0.11% |
| ALTRINSIC GLOBAL ADVISORS LLC | 168,800 | $2,507,000 | 0.08% |
| Inspire Investing, LLC | 31,868 | $473,000 | 0.06% |
| DUALITY ADVISERS, LP | 51,196 | $760,000 | 0.06% |